In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by ...
The strategy, which they demonstrated in cells in the lab, forces brain cancer cells to display targets for the immune system to ... Researchers Home in on Tumor Vulnerabilities to Improve Odds of ...
Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI assay. In ...